Fig. 5: TMEM173 facilitates pancreatic tumorigenesis.

a Survival of Pdx1-Cre;KrasG12D/+;Gpx4−/− (KCG) or Pdx1-Cre;KrasG12D/+; Gpx4−/−;Tmem173−/− (KCGT) mice with or without control IgG or anti-8-OHG antibody treatment (n = 10 mice/group; log-rank [Mantel–Cox] test). b Pancreatic weight of the indicated mice (6 months; n = 5 mice/group; two-way ANOVA with Tukey’s multiple comparisons test). c Representative pancreas histology of the indicated mice. d Percentages of histological structures in the pancreas of the indicated mice (n = 5 mice/group; two-way ANOVA with Tukey’s multiple comparisons test). e Representative images of immunofluorescence staining of macrophages (red) in pancreas in indicated mice at the age of 3 months. f Relative gene expression in the pancreas of the indicated mice (n = 3 mice/group; two-way ANOVA with Tukey’s multiple comparisons test). g Percentage of abnormal telomeres by FISH analysis in ductal cells from KCG and KCGT mice at 3 months of age (n = 5 mice/genotype). h mRNA expression of Tmem173 in indicated mice at 3 months of age with or without clophosome treatment (n = 3 mice/group; two-way ANOVA with Tukey’s multiple comparisons test). Data in b, d, and f–h are presented as mean ± SD. Data are from two or three independent experiments.